Biotech Startups

ONTOFORCE provides data science solutions and support services centered around DISQOVER, guiding customers through implementation, customization, and ongoing support to meet their specific needs.

3 investors

Open Bionics develops 3D-printed bionic hands called the Hero Arm, designed to be affordable, functional, and aesthetically appealing alternatives to traditional prostheses. The company serves individuals with upper limb differences and limb loss, operating in the medical devices and assistive technology space.

3 investors

Opo develops bio-based ingredients and cell lines for cosmetic, medical, and cultivated meat applications using synthetic biology and biomanufacturing. The company supplies high-performance biomaterials and multi-species cell banks to biotech and food production customers.

3 investors

Optimeos develops a nanoparticle-based drug formulation and delivery platform (CINCs and LINCs) for complex biologics including mRNA, DNA, peptides, and proteins, targeting rare diseases, immunology, and metabolic conditions such as obesity. Its technology enables intracellular and long-acting delivery for pharmaceutical and biotech partners addressing challenges like tissue targeting and dosing profiles.

3 investors

Optinose is a specialty pharmaceutical company that develops and markets products for patients with conditions treated by ear, nose, and throat (ENT) and allergy specialists. Its lead product, XHANCE (fluticasone propionate), uses the company's patented Bi-Directional Exhalation Delivery System (EDS) to deliver medication deep into the nasal passages.

3 investors

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases (IRDs) and other retinal and refractive disorders. It focuses on genetic medicine aimed at preserving and restoring vision for patients with rare eye conditions.

3 investors

Orakl Oncology, a spin-off from Gustave Roussy, builds an AI-and-biology platform that grows patient-derived tumor organoids and enriches them with genomic, transcriptomic, phenotypic, and clinical data to predict drug response and clinical trial outcomes. It offers O-Predict for anticipating clinical endpoints and biomarkers and O-Target for therapeutic target discovery, serving biopharma companies in oncology drug discovery and development.

3 investors

Oral Genome offers a saliva-based, point-of-care testing platform that uses a smartphone app to analyze a test card and identify oral and whole-body health risk indicators within minutes. It is designed for dental, medical, institutional, and individual use across clinical, public-health, and community settings.

3 investors

Orbit works on complex problems in neuroscience.

3 investors

A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.

3 investors

OrganoidSciences develops organoid-based regenerative therapeutics and evaluation solutions, operating dedicated GMP manufacturing facilities for cell/organoid drug production. Its lead program ATORM-C is an organoid therapy for inflammatory bowel disease, with clinical development across Korea, the US, and Europe.

3 investors

Oricell Therapeutics (原启生物) is a clinical-stage biopharmaceutical company developing cell therapies, including CAR-T products targeting GPRC5D for relapsed/refractory multiple myeloma and GPC3 for advanced liver cancer. Based in Shanghai, it builds proprietary antibody and CAR platforms (OriAb, OriCAR) to create cancer immunotherapies for unmet oncology needs such as liver, gastric, pancreatic, biliary, and ovarian cancers.

3 investors

Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.

3 investors

OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways. The company targets patients with metabolic diseases through precision therapeutic approaches.

3 investors

Unable to determine from the page provided. The team page contains only a biographical entry for a pain management physician without company background or product information.

3 investors

Oui Therapeutics develops prescription digital therapeutics aimed at suicide prevention, including what it describes as the first digital therapeutic for suicide, currently in clinical trials. The company works with digital therapy and suicide experts to address suicidal behavior.

3 investors

Ouro Medicines is a biotechnology company developing cell-depleting therapies aimed at resetting the immune system to treat chronic immune-mediated diseases such as autoimmune and autoinflammatory conditions. It is advancing a pipeline of biologics and small molecules across immunology and related therapeutic areas.

3 investors

Ovation provides access to genomic data linked to clinical information at scale to support drug discovery and precision medicine development. The company offers a cloud-based laboratory information management system and a research network that connects clinical laboratories to enable molecular test adoption and biobanking of samples for research.

3 investors

Oxford Science Enterprises is a venture-building investment firm, working in partnership with the University of Oxford, that funds and creates companies based on scientific research from Oxford, Harwell and Culham. It provides capital and company-building support to spin ventures out of academic breakthroughs across deep science fields.

3 investors

Flyttr operates a biosecurity platform that develops and deploys countermeasures against pest threats, combining autonomous pest monitoring systems, AI-powered decision-support, and biological interventions such as engineered Aedes aegypti and Wolbachia. It serves national governments, agricultural authorities, industry partners and field operators across public health, agriculture, and livestock domains.

3 investors

Ozette runs a vertically integrated, AI-enabled lab and platform that generates high-dimensional spectral cytometry data and analyzes it to produce reproducible biomarker endpoints for clinical trials. It serves biopharma clinical development teams, discovery/R&D groups, and academic labs, operating under a validated (GCLP-compliant) quality system.

3 investors

Pacertool develops the PaCRTool-System, a medical device platform and single-use PreSens-Catheter that measures a proprietary electromechanical biomarker during pacemaker implantation to assess and optimize cardiac resynchronization therapy (CRT). It targets cardiologists treating patients with dyssynchronous heart failure, aiming to identify when pacemaker treatment is effective and enable personalized therapy.

3 investors

3 investors

Palland Tx is developing next-generation targeted protein degraders aimed at improving therapeutic efficacy through precision targeting. The company operates in the biotech and therapeutics space, though its website is still in a pre-launch "coming soon" state.

3 investors